Cargando…

Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells

BACKGROUND: Nowadays, there is a considerable gap in knowledge concerning the mechanism(s) by which long-acting β(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) interact to induce bronchodilation. This study aimed to characterise the pharmacological interaction between glycopyrro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazzola, Mario, Calzetta, Luigino, Puxeddu, Ermanno, Ora, Josuel, Facciolo, Francesco, Rogliani, Paola, Matera, Maria Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906998/ https://www.ncbi.nlm.nih.gov/pubmed/27296533 http://dx.doi.org/10.1186/s12931-016-0386-8

Ejemplares similares

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways
por: Calzetta, Luigino, et al.
Publicado: (2018)

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences
por: Cazzola, Mario, et al.
Publicado: (2023)

The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils
por: Rogliani, Paola, et al.
Publicado: (2016)

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
por: Rogliani, Paola, et al.
Publicado: (2017)

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
por: Rogliani, Paola, et al.
Publicado: (2019)

The future of inhalation therapy in chronic obstructive pulmonary disease
por: Cazzola, Mario, et al.
Publicado: (2022)

Hyperglycaemia and Chronic Obstructive Pulmonary Disease
por: Cazzola, Mario, et al.
Publicado: (2023)

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine
por: Rogliani, Paola, et al.
Publicado: (2019)

Airflow obstruction: is it asthma or is it COPD?
por: Rogliani, Paola, et al.
Publicado: (2016)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score
por: Rogliani, Paola, et al.
Publicado: (2022)

Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
por: Cazzola, Mario, et al.
Publicado: (2017)

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement
por: Manzetti, Gian Marco, et al.
Publicado: (2023)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine
por: Calzetta, Luigino, et al.
Publicado: (2017)

Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review
por: Rogliani, Paola, et al.
Publicado: (2020)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients
por: Calzetta, Luigino, et al.
Publicado: (2019)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

Strength of association between comorbidities and asthma: a meta-analysis
por: Rogliani, Paola, et al.
Publicado: (2023)

Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy
por: Cazzola, Mario, et al.
Publicado: (2020)

Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review
por: Matera, Maria Gabriella, et al.
Publicado: (2020)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Editorial overview: Respiratory: Pulmonary pharmacology–The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives
por: Cazzola, Mario, et al.
Publicado: (2021)

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma
por: Calzetta, Luigino, et al.
Publicado: (2023)

Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent
por: Cazzola, Mario, et al.
Publicado: (2020)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Guidance on nebulization during the current COVID-19 pandemic
por: Cazzola, Mario, et al.
Publicado: (2021)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Treatable Mechanisms in Asthma
por: Cazzola, Mario, et al.
Publicado: (2021)

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
por: Cazzola, Mario, et al.
Publicado: (2021)

Use of Thiols in the Treatment of COVID-19: Current Evidence
por: Cazzola, Mario, et al.
Publicado: (2021)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
por: Rossi, Andrea, et al.
Publicado: (2015)

Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method
por: Zayed, Sahar, et al.
Publicado: (2017)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gjksnndufbcaq3v05nl6l5sgs2